A controlled trial of azathioprine in Crohn's disease - PubMed (original) (raw)

Clinical Trial

A controlled trial of azathioprine in Crohn's disease

J L Rosenberg et al. Am J Dig Dis. 1975 Aug.

Abstract

To determine the efficacy of azathioprine in the treatment of Crohn's disease, a 26-week double-blind trial was performed. 20 patients with Crohn's disease, requiring at least 10 mg of prednisone/day over the 3 months prior to entering the study were randomized into placebo (10 patients) and major criterion of success in the trial. There were 7 relapses in the placebo group (5 patients) and 2 relapses in the azathioprine group (2 patients). Complications including fistulae were not affected by the medications. The mean reduction in steriod dosage in the azathioprine group at the end of the trial (-15.5 mg) was greater than in the placebo group (-6.1 mg). These results suggest that azathioprine may permit reduction or discontinuation of steroids without the worsening of symptoms in some patients who appear to require steroids for control of their symptoms. The clinical features of this "AZA-responsive subgroup" remain to be defined.

PubMed Disclaimer

References

    1. Ann Intern Med. 1973 Nov;79(5):694-700 - PubMed
    1. Lancet. 1971 Dec 11;2(7737):1273-6 - PubMed
    1. Am J Dig Dis. 1971 Apr;16(4):327-32 - PubMed
    1. Lancet. 1971 Oct 30;2(7731):944-7 - PubMed
    1. Lancet. 1969 Sep 20;2(7621):612-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources